Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9644025 Immunotherapy regimes dependent on ApoE status

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Date Filed
October 17, 2008
Date of Patent
May 9, 2017
Patent Application Number
12738396
Patent Citations Received
‌
US Patent 11779629 Compositions comprising cyclic peptides derived from an A-beta peptide
‌
US Patent 12071472 Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
0
‌
US Patent 11970522 Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
0
‌
US Patent 11905318 Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9644025
Patent Primary Examiner
‌
Kimberly A Ballard

Find more entities like US Patent 9644025 Immunotherapy regimes dependent on ApoE status

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.